Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 15/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 7/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485617 | 0.89 | LMNA (0.47) | LMNAGAASMN1; SMN2NPSR1CACNA1B | |
| SCHEMBL22951219 | 0.88 | KDM4E (0.45) | LMNAGAASMN1; SMN2 | |
| SCHEMBL22951216 | 0.88 | ALDH1A1 (0.45) | LMNAGAASMN1; SMN2NPSR1 | |
| SCHEMBL4396159 | 0.87 | CACNA1B (0.61) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL3485614 | 0.85 | GAA (0.50) | LMNAGAASMN1; SMN2NPSR1CACNA1B | |
| SCHEMBL8236293 | 0.84 | CACNA1B (0.51) | GAACACNA1BNR1I2CYP3A4 | |
| SCHEMBL3485524 | 0.84 | CACNA1B (0.50) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL3485605 | 0.83 | UBE2M (0.47) | LMNAGAASMN1; SMN2NPSR1CACNA1B | |
| SCHEMBL12542343 | 0.83 | CNR1 (0.49) | LMNAGAASMN1; SMN2NPSR1CACNA1B | |
| SCHEMBL3763660 | 0.83 | CACNA1B (0.47) | LMNAGAASMN1; SMN2CACNA1BNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937181-B2 | Benzenesulfonamide compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2015-01-20 | — | — | US | claimed |
| US-20090306136-A1 | Benzenesulfonamide Compounds and the Use Thereof | PURDUE PHARMA L.P. | 2009-12-10 | — | — | US | claimed |
| WO-2007118854-A1 | BENZENESULFONAMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2007-10-25 | — | — | WO | claimed |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-20 | — | — | US | disclosed |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-09-23 | — | — | US | disclosed |
| US-10729664-B2 | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190216747-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION | 2019-07-18 | — | — | US | disclosed |
| US-8937181-B2 | Benzenesulfonamide compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937181-B2 | Benzenesulfonamide compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937181-B2 | Benzenesulfonamide compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20120172429-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS | THE GENERAL HOSPITAL CORPORATION | 2012-07-05 | — | — | US | disclosed |
| US-20090306136-A1 | Benzenesulfonamide Compounds and the Use Thereof | PURDUE PHARMA L.P. | 2009-12-10 | — | — | US | disclosed |
| US-20090306136-A1 | Benzenesulfonamide Compounds and the Use Thereof | PURDUE PHARMA L.P. | 2009-12-10 | — | — | US | disclosed |
| US-20090306136-A1 | Benzenesulfonamide Compounds and the Use Thereof | PURDUE PHARMA L.P. | 2009-12-10 | — | — | US | disclosed |
| WO-2007118854-A1 | BENZENESULFONAMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118854-A1 | BENZENESULFONAMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172429-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | LMNA 764/4885GAA 2732/4885SMN1; SMN2 1185/4885 |
| US-10729664-B2 | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents | TRPV1, CACNA1B, ORAI1 | LMNA 764/4885GAA 2732/4885SMN1; SMN2 1185/4885 |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | OPRL1, MRGPRX1, RAMP1 | LMNA 2620/4885GAA 3996/4885SMN1; SMN2 1712/4885 |
| US-20090306136-A1 | Benzenesulfonamide Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1B | LMNA 2472/4885GAA 2156/4885SMN1; SMN2 1294/4885 |
| US-20190216747-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | LMNA 764/4885GAA 2732/4885SMN1; SMN2 1185/4885 |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | LMNA 764/4885GAA 2732/4885SMN1; SMN2 1185/4885 |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CACNA1B, TRPV1, ORAI1 | LMNA 786/4885GAA 2636/4885SMN1; SMN2 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.